Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Overweight and raises the price target from $285 to $300.